中医诊治克罗恩病的临床研究进展

姚钧仁, 刘育辰, 单静怡, 等. 中医诊治克罗恩病的临床研究进展[J]. 中国中西医结合消化杂志, 2024, 32(5): 444-449. doi: 10.3969/j.issn.1671-038X.2024.05.14
引用本文: 姚钧仁, 刘育辰, 单静怡, 等. 中医诊治克罗恩病的临床研究进展[J]. 中国中西医结合消化杂志, 2024, 32(5): 444-449. doi: 10.3969/j.issn.1671-038X.2024.05.14
YAO Junren, LIU Yuchen, SHAN Jingyi, et al. Clinical research progress on traditional Chinese medicine diagnosis and treatment of Crohn's disease[J]. Chin J Integr Tradit West Med Dig, 2024, 32(5): 444-449. doi: 10.3969/j.issn.1671-038X.2024.05.14
Citation: YAO Junren, LIU Yuchen, SHAN Jingyi, et al. Clinical research progress on traditional Chinese medicine diagnosis and treatment of Crohn's disease[J]. Chin J Integr Tradit West Med Dig, 2024, 32(5): 444-449. doi: 10.3969/j.issn.1671-038X.2024.05.14

中医诊治克罗恩病的临床研究进展

  • 基金项目:
    国家自然科学基金项目(No: 82104743); 海派中医流派传承创新团队建设项目(No: 2021LPTD-009); 上海市进一步加快中医药传承创新发展三年行动计划(2020年-2023年)项目(No: ZY(2021-2023)-0207-01)
详细信息

Clinical research progress on traditional Chinese medicine diagnosis and treatment of Crohn's disease

More Information
  • 克罗恩病(CD)是一种病因未明、可累及全消化道的特发性炎症性疾病,本病病程迁延反复,以腹痛、腹泻、瘘管形成等为主要症状。目前西医治疗存在治疗达标率低、复发率较高、不良反应较多等不足。中医诊治CD尚处于起步阶段,研究发现中医药在缓解症状、抑制炎症反应、改善凝血功能、促进黏膜愈合、提高生物制剂临床应答率、减少复发率及治疗肛周并发症等方面具有作用。本文对近10年来中医对CD的病因病机的认识、中医辨证分型和中医治疗的文献进行综述。
  • 加载中
  • [1]

    Roda G, Ng SC, Kotze PG, et al. Crohn's disease[J]. Nat Rev Dis Primers, 2020, 6(1): 22. doi: 10.1038/s41572-020-0156-2

    [2]

    陈旻湖, 杨云生, 唐承薇. 消化病学[M]. 北京: 人民卫生出版社, 2019: 259-269.

    [3]

    Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment[J]. J Crohns Colitis, 2020, 14(2): 155-168. doi: 10.1093/ecco-jcc/jjz187

    [4]

    周吴平, 穆楠, 简伟研, 等. 克罗恩病患者疾病经济负担现状与相关因素[J]. 北京大学学报(医学版), 2021, 53(3): 555-559. https://www.cnki.com.cn/Article/CJFDTOTAL-BYDB202103020.htm

    [5]

    Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0

    [6]

    Yang H, Zhou R, Bai X, et al. Trend and Geographic Variation in Incidence and Prevalence of Inflammatory Bowel Disease in Regions Across China: A Nationwide Employee Study Between 2013 and 2016[J]. Front Med(Lausanne), 2022, 9: 900251.

    [7]

    Li N, Shi RH. Updated review on immune factors in pathogenesis of Crohn's disease[J]. World J Gastroenterol, 2018, 24(1): 15-22. doi: 10.3748/wjg.v24.i1.15

    [8]

    Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases[J]. Mayo Clin Proc, 2019, 94(1): 155-165. doi: 10.1016/j.mayocp.2018.09.013

    [9]

    Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications[J]. J Crohns Colitis, 2019, 13(2): 144-164. doi: 10.1093/ecco-jcc/jjy113

    [10]

    李伟康, 李鲜, 陈乾, 等. 中西医治疗克罗恩病研究进展[J]. 中国中西医结合消化杂志, 2023, 31(5): 391-396. doi: 10.3969/j.issn.1671-038X.2023.05.13

    [11]

    Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment[J]. J Crohns Colitis, 2020, 14(1): 4-22. doi: 10.1093/ecco-jcc/jjz180

    [12]

    Cucchiara S, D'Arcangelo G, Isoldi S, et al. Mucosal healing in Crohn's disease: new insights[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(5): 335-345. doi: 10.1080/17474124.2020.1759416

    [13]

    Li J, Liu Z, Hu P, et al. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study[J]. BMC Gastroenterol, 2022, 22(1): 44. doi: 10.1186/s12876-021-02074-z

    [14]

    Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse[J]. Clin Gastroenterol Hepatol, 2009, 7(1): 80-85. doi: 10.1016/j.cgh.2008.08.028

    [15]

    Buhl SS, Steenholdt C, Brynskov J, et al. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission(the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial[J]. BMJ Open, 2014, 4(12): e005887. doi: 10.1136/bmjopen-2014-005887

    [16]

    Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease[J]. Am Fam Physician, 2011, 84(12): 1365-1375.

    [17]

    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease[J]. Gastroenterology, 2008, 134(4): 929-936. doi: 10.1053/j.gastro.2008.01.012

    [18]

    Loftus EV, Sloan S, Ramachandran P, et al. Comparison of Rates of Active Tuberculosis Infection in the Phase 2 and 3 Clinical Trial Programs for Anti-IL12/23 and Anti-TNFS[J]. Gastroenterology, 2017, 152(5): S596.

    [19]

    沈洪, 张声生, 王垂杰, 等. 中药分期序贯治疗轻中度溃疡性结肠炎临床观察[J]. 中华中医药杂志, 2012, 27(7): 1788-1791. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201207019.htm

    [20]

    Naganuma M, Sugimoto S, Mitsuyama K, et al. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis[J]. Gastroenterology, 2018, 154(4): 935-947. doi: 10.1053/j.gastro.2017.11.024

    [21]

    田明健, 肖瑞崇, 李东书. 基于经典理论和文献资料探讨克罗恩病中医诊疗[J]. 辽宁中医药大学学报, 2017, 19(9): 156-158. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB201709048.htm

    [22]

    赵延华, 赵智强. 略论克罗恩病的中医认识[J]. 南京中医药大学学报, 2014, 30(5): 410-412. doi: 10.3969/j.issn.1000-5005.2014.05.004

    [23]

    陈锦锋. 克罗恩病中医证治探讨[J]. 中医药导报, 2017, 23(5): 9-11. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB201705004.htm

    [24]

    黄智斌, 老膺荣, 魏裕涛, 等. 于数据挖掘中医治疗克罗恩病的用药规律分析[J]. 中国医药科学, 2022, 12(1): 67-71. doi: 10.3969/j.issn.2095-0616.2022.01.018

    [25]

    莫黎, 谢彪, 何永恒. 何永恒教授论治克罗恩病经验[J]. 湖南中医药大学学报, 2021, 41(9): 1418-1421. doi: 10.3969/j.issn.1674-070X.2021.09.018

    [26]

    屈钰珂, 朱莹. 从"毒伏筋膜"理论辨证论治克罗恩病[J]. 世界中西医结合杂志, 2023, 18(8): 1673-1677. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202308030.htm

    [27]

    梁国英, 张浩冉, 崔海栋, 等. 谢晶日教授诊治克罗恩病经验撷要[J]. 现代中西医结合杂志, 2023, 32(4): 552-555. doi: 10.3969/j.issn.1008-8849.2023.04.024

    [28]

    李乾构, 周学文, 单兆伟. 中医消化病诊疗指南[M]. 北京: 中国中医药出版社, 2006: 87-87.

    [29]

    陈珊, 韩树堂. 克罗恩病的辨证论治[J]. 山东中医杂志, 2012, 31(5): 331-332. https://www.cnki.com.cn/Article/CJFDTOTAL-SDZY201205015.htm

    [30]

    吕永慧. 克罗恩病的中医诊治思路[J]. 现代消化及介入诊疗, 2010, 15(4): 244-247. doi: 10.3969/j.issn.1672-2159.2010.04.014

    [31]

    陈颖. 克罗恩病的辨证论治及针灸治疗的研究进展[J]. 中国中医急症, 2019, 28(7): 1313-1316. doi: 10.3969/j.issn.1004-745X.2019.07.055

    [32]

    王园园, 张驰, 刘红华, 等. 中医药治疗克罗恩病的研究进展[J]. 湖南中医杂志, 2018, 34(11): 168-170. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZO201811084.htm

    [33]

    罗曌, 宾东华, 王爱华. 王爱华教授辨治克罗恩病经验[J]. 亚太传统医药, 2021, 17(5): 101-103. https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT202105030.htm

    [34]

    钟燕桃, 陈延. 广东地区克罗恩病的中医证型分布特征研究[J]. 中医临床研究, 2017, 9(18): 107-110. doi: 10.3969/j.issn.1674-7860.2017.18.053

    [35]

    林志宾, 郑明岚. 基于数据挖掘中药治疗克罗恩病的用药规律分析[J]. 中医临床研究, 2022, 14(21): 7-11. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202221003.htm

    [36]

    陈茜. 粪钙卫蛋白与克罗恩病及其中医证型关系的研究[D]. 杭州: 浙江中医药大学, 2019.

    [37]

    杨丽艳, 赵宝宁, 杨贺庆, 等. 半夏泻心汤联合美沙拉嗪治疗轻度活动期克罗恩病疗效研究[J]. 陕西中医, 2021, 42(9): 1240-1242. doi: 10.3969/j.issn.1000-7369.2021.09.023

    [38]

    张毅, 周进. 益肝扶脾方联合甲氨蝶呤对肝郁脾虚型克罗恩病中重度患者IL-23/Th17炎症通路的影响[J]. 四川中医, 2021, 39(11): 112-115. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY202111034.htm

    [39]

    朱笑吉, 吴璐一, 郑寒丹, 等. 近20年针灸治疗克罗恩病的临床研究与选穴规律[J]. 世界中医药, 2023, 18(4): 482-490. doi: 10.3969/j.issn.1673-7202.2023.04.007

    [40]

    包春辉, 钟捷, 刘慧荣, 等. 针灸对活动期克罗恩病患者负性情绪及血浆色氨酸代谢的影响[J]. 中国针灸, 2021, 41(1): 17-22. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZE202101008.htm

    [41]

    罗曼虹. 柴胡疏肝散合参苓白术散对肝郁脾虚型克罗恩病的临床疗效及对免疫功能的影响[J]. 临床医学工程, 2019, 26(3): 317-319. doi: 10.3969/j.issn.1674-4659.2019.03.0317

    [42]

    江海垠, 王建民, 李明. 参苓白术散联合美沙拉嗪肠溶片治疗脾虚湿盛证轻中度克罗恩病的临床研究[J]. 江西中医药大学学报, 2023, 35(3): 52-56. https://www.cnki.com.cn/Article/CJFDTOTAL-XYXB202303011.htm

    [43]

    鲍亦晨, 尹天雷. 香连丸联合美沙拉嗪治疗湿热蕴结型克罗恩病的临床研究[J]. 中国医学创新, 2022, 19(2): 155-159. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202202041.htm

    [44]

    孔鹏飞, 魏先鹏, 唐学贵. 桃花汤合补中益气汤加减对克罗恩病Th1和Th17细胞因子的影响[J]. 中国实验方剂学杂志, 2019, 25(24): 54-59. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201924013.htm

    [45]

    Zubcevic N, Mesihovic R, Zubcevic S. Usefulness of laboratory data in estimation of Crohn's disease activity[J]. Med Arh, 2010, 64(1): 33-36.

    [46]

    Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20(17): 4857-4872.

    [47]

    郭易娟, 梅浙川. 炎症性肠病血液高凝状态的研究进展[J]. 重庆医学, 2016, 45(5): 704-706. https://www.cnki.com.cn/Article/CJFDTOTAL-CQYX201605045.htm

    [48]

    Kume K, Yamasaki M, Tashiro M, et al. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis[J]. Intern Med, 2007, 46(17): 1323-1329.

    [49]

    徐速, 陈浩, 曾莉. 三棱丸方对克罗恩病肠纤维化中血小板活化治疗作用的研究[J]. 陕西中医, 2017, 38(2): 144-146. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZY201702003.htm

    [50]

    徐治中, 杜骏, 杨筱, 等. 血竭散联合英夫利西单抗治疗克罗恩病的临床疗效观察[J]. 中国中西医结合外科杂志, 2022, 28(3): 331-335. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZX202203009.htm

    [51]

    侯献君. 阳和汤加减治疗克罗恩病的效果及对患者黏膜愈合情况的影响[J]. 现代实用医学, 2020, 32(2): 178-179, 219. https://www.cnki.com.cn/Article/CJFDTOTAL-NBYX202002017.htm

    [52]

    Manlay L, Boschetti G, Pereira B, et al. Comparison of short-and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy[J]. Aliment Pharmacol Ther, 2021, 53(12): 1289-1299.

    [53]

    焦亚云, 李英, 陈昊. 铺姜灸联合阿达木单抗治疗轻、中度活动期脾虚湿蕴型克罗恩病30例临床研究[J]. 江苏中医药, 2022, 54(9): 39-43. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202209014.htm

    [54]

    周天翔. 姜黄水煎剂灌肠应用于克罗恩病治疗的临床研究[D]. 南京: 南京中医药大学, 2017.

    [55]

    赵雷, 赵玉瑶, 赵法新. 扶正活血汤联合英夫利昔单抗治疗克罗恩病[J]. 中医学报, 2022, 37(5): 1071-1075. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK202205030.htm

    [56]

    Sun J, Shen X, Dong J, et al. Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn's Disease[J]. Am J Med Sci, 2015, 350(5): 345-351.

    [57]

    张萌, 张向东, 夏永欣, 等. 参苓白术散合附子理中丸联合西药治疗克罗恩病临床研究[J]. 新中医, 2019, 51(12): 73-76. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201912024.htm

    [58]

    Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation[J]. Gastroenterology, 2004, 126(6): 1518-1532.

    [59]

    王佳雯, 董若曦, 叶孙送, 等. 红萸饮联合切开拖线疗法治疗克罗恩病肛瘘的回顾性临床研究[J]. 上海中医药杂志, 2021, 55(6): 53-57. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ202106015.htm

    [60]

    邱丽娟, 肖秋平, 林丽珠. 中西医结合治疗克罗恩病合并肛瘘的临床效果[J]. 中国当代医药, 2019, 26(14): 196-199. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201914058.htm

  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  145
  • 施引文献:  0
出版历程
收稿日期:  2023-12-30
刊出日期:  2024-05-15

返回顶部

目录